Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 129,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit www.novartis.com.
Novartis is on Twitter. Sign up to follow @Novartis at twitter.com/novartis.
POSTED
02-26-20
Novartis and DNDi to Collaborate on the Development of a New Oral Drug to Treat Visceral Leishmaniasis
Novartis and the Drugs for Neglected Diseases initiative (DNDi), a not-for-profit research and development (R&D) organization, have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, ...
POSTED
02-03-20
Just Released: 2019 Novartis in Society Report, Detailing Progress Made on Environmental, Social and Governance (ESG) Topics
February 3, 2020 - For the seventh consecutive year, Novartis is publishing an annual Novartis in Society ESG report. The report has been prepared in accordance with the GRI Standards: Core option. It supplements the “Build trust with society” section in the 2019 Novartis A...
POSTED
01-16-20
Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People
Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to increase access to community-based primary healthcare for nearly 1.7 million people in up to six African countries, as part of their shared ...
POSTED
11-26-19
Novartis Supports EDCTP’s Career Development Programme, Focusing on Maternal and Child Health
Novartis will support the career development programme of the European & Developing Countries Clinical Trials Partnership (EDCTP). The programme aims to provide early- to mid-career researchers in sub-Saharan Africa with an opportunity to train and develop their clinical research skills.
...
POSTED
11-13-19
Novartis annonce une nouvelle stratégie pour fournir des traitements innovants à plus de patients en Afrique subsaharienne
Novartis a annoncé aujourd’hui une nouvelle stratégie visant à élargir l’accès des patients et la disponibilité de sa gamme de médicaments en Afrique subsaharienne, qui regroupe la plus vaste population au monde de patients mal desservis. Novartis souhaite également être le partenaire de choix de...
POSTED
11-13-19
Novartis Announces New Strategy to Provide Innovative Medicines to More Patients in Sub-Saharan Africa
Novartis announced today a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest underserved patient population in the world. Novartis also aspires to be the partner of choice for governments and NGOs to stre...
POSTED
11-11-19
Government of Ghana Makes Hydroxyurea Available to People With Sickle Cell Disease Through First of Its Kind Public-private Partnership With Global Medicines Company Novartis
Today, the Government of Ghana announced the availability of hydroxyurea for the treatment of people with sickle cell disease (SCD), marking the official launch of a first of its kind public-private partnership to improve the diagnosis and accelerate treatment for people with SCD. The launch foll...
POSTED
06-20-19
Uncovering Sickle Cell Disease
Every day, people endure the painful and life-threatening symptoms of sickle cell disease in the shadows because of fear, stigma,and isolation.1,2,3
Today, on World Sickle Cell Day, Novartis is helping raise awareness on the disease and its complications by sharing a collection ...
POSTED
04-15-19
Europe-Africa Partnership Spearheads Development of Next-generation Antimalarial Drug
The European & Developing Countries Clinical Trials Partnership (EDCTP) has granted new funding of €10m over five years to support late-stage clinical trials of a next-generation antimalarial combination including KAF156 (ganaplacide). The trials will be conducted in four countries in West an...
POSTED
02-04-19
Novartis Releases Novartis in Society 2018 Report
For the sixth consecutive year, Novartis is publishing an annual Novartis in Society report (formerly our Corporate Responsibility Report).
The report is divided into four chapters based on our corporate responsibility (CR) material clusters and the global health and CR strategic prioritie...
